KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Equity Average (2018 - 2025)

Aquestive Therapeutics has reported Equity Average over the past 8 years, most recently at -$18.9 million for Q4 2025.

  • Quarterly results put Equity Average at -$18.9 million for Q4 2025, up 64.22% from a year ago — trailing twelve months through Dec 2025 was -$18.9 million (up 64.22% YoY), and the annual figure for FY2025 was -$46.9 million, up 43.7%.
  • Equity Average for Q4 2025 was -$18.9 million at Aquestive Therapeutics, up from -$38.3 million in the prior quarter.
  • Over the last five years, Equity Average for AQST hit a ceiling of -$18.9 million in Q4 2025 and a floor of -$113.9 million in Q1 2023.
  • Median Equity Average over the past 5 years was -$69.0 million (2021), compared with a mean of -$72.3 million.
  • Biggest five-year swings in Equity Average: plummeted 272.14% in 2021 and later surged 66.75% in 2024.
  • Aquestive Therapeutics' Equity Average stood at -$71.2 million in 2021, then crashed by 58.88% to -$113.2 million in 2022, then rose by 7.49% to -$104.7 million in 2023, then surged by 49.59% to -$52.8 million in 2024, then soared by 64.22% to -$18.9 million in 2025.
  • The last three reported values for Equity Average were -$18.9 million (Q4 2025), -$38.3 million (Q3 2025), and -$66.8 million (Q2 2025) per Business Quant data.